DE202013012742U1 - Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen - Google Patents

Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen Download PDF

Info

Publication number
DE202013012742U1
DE202013012742U1 DE202013012742.2U DE202013012742U DE202013012742U1 DE 202013012742 U1 DE202013012742 U1 DE 202013012742U1 DE 202013012742 U DE202013012742 U DE 202013012742U DE 202013012742 U1 DE202013012742 U1 DE 202013012742U1
Authority
DE
Germany
Prior art keywords
compositions
integer
eye
range
semifluorinated alkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202013012742.2U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaliq GmbH
Original Assignee
Novaliq GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq GmbH filed Critical Novaliq GmbH
Publication of DE202013012742U1 publication Critical patent/DE202013012742U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE202013012742.2U 2012-09-12 2013-09-12 Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen Expired - Lifetime DE202013012742U1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12183997 2012-09-12
EP12183997 2012-09-12

Publications (1)

Publication Number Publication Date
DE202013012742U1 true DE202013012742U1 (de) 2019-01-22

Family

ID=46832270

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202013012742.2U Expired - Lifetime DE202013012742U1 (de) 2012-09-12 2013-09-12 Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen

Country Status (13)

Country Link
US (4) US10449164B2 (enExample)
EP (2) EP3100722B1 (enExample)
JP (3) JP6352266B2 (enExample)
KR (2) KR102158400B1 (enExample)
CN (7) CN113679697A (enExample)
AU (3) AU2013314370B2 (enExample)
BR (1) BR112015004997B1 (enExample)
CA (2) CA2883002C (enExample)
DE (1) DE202013012742U1 (enExample)
ES (2) ES2770398T3 (enExample)
MX (2) MX360469B (enExample)
MY (1) MY166228A (enExample)
WO (1) WO2014041055A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PT2714010T (pt) 2011-05-25 2017-05-05 Novaliq Gmbh Composição farmacêutica tópica à base de alcanos semifluorados
CA2862974C (en) 2012-01-23 2021-11-16 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CA2883003C (en) * 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
ES2687094T3 (es) 2013-07-23 2018-10-23 Novaliq Gmbh Composiciones estabilizadas de anticuerpos
DK3722274T3 (da) * 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
JP7378781B2 (ja) * 2016-09-07 2023-11-14 グリア エルエルシー 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療
CA3036297C (en) * 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
US10751295B2 (en) 2016-11-09 2020-08-25 Specialty Drug and Device, LLC Compositions and methods for the removal of ear wax
ES2965883T3 (es) * 2016-12-23 2024-04-17 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
KR101895321B1 (ko) 2017-04-24 2018-09-05 주식회사 이루다 눈꺼풀의 분비샘 이상에 대한 치료장치
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
EP3618782B1 (en) 2017-05-06 2021-05-26 Novaliq GmbH Drop dispenser
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) * 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
SG11202102818YA (en) * 2018-09-22 2021-04-29 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
JP7360452B2 (ja) 2018-09-27 2023-10-12 ダーマリック セラピューティクス， インコーポレーテッド 脂質バリアの修復
JP7292567B2 (ja) 2018-09-27 2023-06-19 ダーマリック セラピューティクス， インコーポレーテッド 局所日焼け止め製剤
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
SG11202104350RA (en) * 2018-11-27 2021-05-28 Novaliq Gmbh Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2022026805A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for removing meibum or inhibiting meibum buildup
EP4221686A2 (en) * 2020-10-01 2023-08-09 Abionyx Pharma SA Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4247367A4 (en) 2020-11-23 2024-10-16 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2022169788A1 (en) * 2021-02-03 2022-08-11 Ads Therapeutics Llc Topical ophthalmological compositions
TW202327641A (zh) * 2021-09-14 2023-07-16 美商三葉草治療有限公司 使用經修飾之fgf-1多肽之治療方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
US7001607B1 (en) 1999-08-14 2006-02-21 Bausch & Lomb Incorporated Artificial tear replacement solution
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPH0764702B2 (ja) 1986-04-23 1995-07-12 鐘紡株式会社 多相乳化型化粧料
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5849291A (en) 1994-10-17 1998-12-15 Symbollon Corporation Opthalmic non-irritating iodine medicament
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
EP0983037B1 (en) 1998-02-09 2003-05-02 MacroChem Corporation Antifungal nail lacquer
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
EP1105096B1 (en) 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
CN1232244C (zh) 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US6576663B2 (en) 1999-12-22 2003-06-10 Alcon, Inc. 6-Keto prostaglandin F1α and analogs for treating dry eye
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
DE10051937C2 (de) 2000-10-19 2002-11-07 Infineon Technologies Ag Schaltungsanordnung zur Programmierung einer Verzögerungszeit eines Signalpfads
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
JP4806162B2 (ja) 2001-09-04 2011-11-02 トロムスドルフ ゲーエムベーハー ウント コンパニー カーゲー アルツナイミッテル 爪の成長の機能障害および疾患を治療するための硬膏
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP3998596B2 (ja) 2003-03-31 2007-10-31 日本ペイント株式会社 塗膜ムラの算出式算出方法及び塗膜ムラの数値化方法
ES2541488T3 (es) 2003-08-25 2015-07-21 Foamix Pharmaceuticals Ltd. Espuma farmacéutica penetrante
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
EP1684724A4 (en) 2003-11-19 2008-04-02 Barnes Jewish Hospital IMPROVED DRUG DELIVERY
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
ES2387619T3 (es) 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Suplementos de tensioactivos pulmonares
US20050288196A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer contact lens compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
WO2006007510A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
WO2007008666A2 (en) 2005-07-08 2007-01-18 Ocularis Pharma, Inc. Compositions and methods for improving vision using adherent thin films
ES2318802T3 (es) 2005-08-05 2009-05-01 BHARAT SERUMS & VACCINES LTD. Composiciones de emulsion de propofol intravenosas que tienen eficacia conservante.
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
AR062046A1 (es) 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
AU2007281918A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
CA2664879C (en) 2006-09-29 2015-03-24 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
WO2008070490A2 (en) 2006-11-28 2008-06-12 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
KR20090087917A (ko) 2006-12-07 2009-08-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 마이크로리터량의 액체를 방울의 형태로 분배하기 위한 계량된 방울 병
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CA3069576A1 (en) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
HUE032158T2 (en) 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス，インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8669241B2 (en) 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
JP5872453B2 (ja) 2009-04-17 2016-03-01 ナタク ファルマ エセ．エレ． フィタン酸含量が低く、ω−３脂肪酸に富む組成物
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5549669B2 (ja) 2009-06-25 2014-07-16 ライオン株式会社 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法
JP5736635B2 (ja) * 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
DE102010027315A1 (de) 2009-07-24 2011-01-27 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Verfahren zur Entwicklung einer als Schaum auf die Haut zu applizierende flüssige Zusammensetzung sowie eine topisch applizierbare Zusammensetzung
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2819988C (en) 2011-01-04 2019-11-12 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PT2714010T (pt) 2011-05-25 2017-05-05 Novaliq Gmbh Composição farmacêutica tópica à base de alcanos semifluorados
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
CA2862974C (en) 2012-01-23 2021-11-16 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CA2883003C (en) 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
EP2730291A1 (en) 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
WO2014099997A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
CN105142686B (zh) 2013-03-14 2020-04-10 帕恩欧普佳有限公司 给药于眼后段的眼用制剂
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
ES2687094T3 (es) 2013-07-23 2018-10-23 Novaliq Gmbh Composiciones estabilizadas de anticuerpos
AU2014332488B2 (en) 2013-10-09 2017-03-09 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
WO2015153469A1 (en) 2014-03-31 2015-10-08 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
CN106572941B (zh) 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
JP2019504097A (ja) 2016-02-04 2019-02-14 ダイヤー, ゴードン, ウェーンDYER, Gordon, Wayne キャシー・バクスター状態を損なうための方法
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
AU2017380769B2 (en) 2016-12-22 2023-12-21 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
ES2965883T3 (es) 2016-12-23 2024-04-17 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
US7001607B1 (en) 1999-08-14 2006-02-21 Bausch & Lomb Incorporated Artificial tear replacement solution
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
WO2011073134A1 (en) 2009-12-14 2011-06-23 Novaliq Gmbh Pharmaceutical composition for treatment of dry eye syndrome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. Meinert et al., Biomaterials, Artificial Cells, and Immobilization Biotechnology, Bd. 21(5), S. 583-95, 1993
H. Meinert et al., European Journal of Ophthalmology, Bd. 10(3), S. 189-197, 2000
J. L. Gayton, Clinical Ophthalmology 2009:3, 405-412

Also Published As

Publication number Publication date
AU2013314370B2 (en) 2017-11-30
CA2997744C (en) 2019-12-31
CN113952321B (zh) 2023-03-28
KR101874219B1 (ko) 2018-07-03
CA2883002C (en) 2019-05-21
EP3100722B1 (en) 2024-03-20
EP2895158B1 (en) 2019-11-20
CN113694048A (zh) 2021-11-26
US20150224064A1 (en) 2015-08-13
AU2018201364B2 (en) 2019-07-11
KR102158400B1 (ko) 2020-09-22
CN106511322B (zh) 2021-09-17
CN104619314B (zh) 2017-09-22
CN113679698A (zh) 2021-11-23
MY166228A (en) 2018-06-22
EP3100722C0 (en) 2024-03-20
JP2015531344A (ja) 2015-11-02
HK1210041A1 (en) 2016-04-15
US20200188318A1 (en) 2020-06-18
CN113679697A (zh) 2021-11-23
KR20150054996A (ko) 2015-05-20
MX360469B (es) 2018-11-05
WO2014041055A1 (en) 2014-03-20
CN113679698B (zh) 2022-07-26
MX2015003229A (es) 2015-11-16
CN106511322A (zh) 2017-03-22
KR20160104747A (ko) 2016-09-05
JP6253717B2 (ja) 2017-12-27
BR112015004997B1 (pt) 2022-09-13
CN113679699A (zh) 2021-11-23
JP6352266B2 (ja) 2018-07-04
JP2016193931A (ja) 2016-11-17
AU2016219611A1 (en) 2016-09-15
CA2883002A1 (en) 2014-03-20
CN113694048B (zh) 2023-03-24
AU2016219611B2 (en) 2018-03-01
BR112015004997A2 (pt) 2017-07-04
US12005033B2 (en) 2024-06-11
US10369117B2 (en) 2019-08-06
MX363182B (es) 2019-03-13
CN104619314A (zh) 2015-05-13
ES2770398T3 (es) 2020-07-01
ES2974663T3 (es) 2024-07-01
CN113679699B (zh) 2022-10-28
AU2018201364A1 (en) 2018-03-15
US10449164B2 (en) 2019-10-22
US20240350425A1 (en) 2024-10-24
JP2018111704A (ja) 2018-07-19
US20180071229A1 (en) 2018-03-15
EP2895158A1 (en) 2015-07-22
EP3100722A1 (en) 2016-12-07
CA2997744A1 (en) 2014-03-20
AU2013314370A1 (en) 2015-03-26
CN113952321A (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
US20240350425A1 (en) Compositions comprising mixtures of semifluorinated alkanes
EP3181119B1 (en) Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca
HK1233187A1 (en) Compositions comprising mixtures of semifluorinated alkanes
HK1231778A1 (en) Semifluorinated alkanes for use in solubilizing meibum
HK1231778B (en) Semifluorinated alkanes for use in solubilizing meibum
HK1210041B (en) Compositions comprising mixtures of semifluorinated alkanes
HK1240112B (en) Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca

Legal Events

Date Code Title Description
R082 Change of representative

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R207 Utility model specification
R150 Utility model maintained after payment of first maintenance fee after three years
R163 Identified publications notified
R151 Utility model maintained after payment of second maintenance fee after six years
R082 Change of representative

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right